Consistent with clinical findings, a recent study demonstrated that sodium selenate treatment improved cognitive impairment and neuropsychiatric symptoms by reducing the accumulation of tau protein in the hippocampus of PS1/APP/tau triple transgenic AD model (3xTg-AD) mice (Van Der Jeugd et al., 2018). The gene discussed is MAPT; the disease is Alzheimer disease.